We are live on ! Find out more
KAPA icon

Kairos Pharma
KAPA

10 hedge funds and large institutions have $173K invested in Kairos Pharma in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

25% more funds holding

Funds holding: 8 → 10 (+2)

10.21% less ownership

Funds ownership: 11.51% → 1.3% (-10%)

94% less capital inflows, than outflows

Capital inflows: $77.8K | Capital outflows: $1.37M

Holders
10
Holders Change
+2
Holders Change %
+25%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
3
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
XTX Topco
XTX Topco
Cayman Islands
+$45.7K
2
Two Sigma Securities
Two Sigma Securities
New York
+$9.9K
3
HRT Financial
HRT Financial
New York
+$9.6K
4
UBS Group
UBS Group
Switzerland
+$4.85K
5
Citigroup
Citigroup
New York
+$4K

Top Sellers

Rank Fund Capital Flow
1
Armistice Capital
Armistice Capital
New York
-$1.31M
2
Scientech Research LLC
Scientech Research LLC
New Jersey
-$45.1K
3
Citadel Advisors
Citadel Advisors
Florida
-$12.4K

KAPA Hedge Fund Activity: Q2 2025 in Review

10 of the 7,629 institutional investors tracked by Wall St. Rank reported a position in Kairos Pharma (KAPA) for Q2 2025, worth a combined $173K — down 88% from $1.46M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new KAPA positions and 3 closed out — a net gain of 2 holders — while 3 added to existing stakes and 0 trimmed.

The largest buyer was XTX Topco, opening a new position worth an estimated $45.7K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.31M sold.

  • 10 institutional investors held Kairos Pharma (KAPA) as of Q2 2025, up from 8 in Q1 2025.
  • Funds reported $173K of Kairos Pharma stock for Q2 2025, down 88% quarter-over-quarter.
  • 5 funds opened new Kairos Pharma positions in Q2 2025 and 3 closed out, a net change of +2 holders.
  • The largest Kairos Pharma buyer in Q2 2025 was XTX Topco, an estimated $45.7K added.
  • The largest Kairos Pharma seller in Q2 2025 was Armistice Capital, an estimated $1.31M sold.

Based on aggregated 13F filings for Q2 2025.